CONTEXT: Parenteral administration of peptideGnRH analogs is widely employed for treatment of endometriosis and fibroids and in assisted-reproductive therapy protocols. Elagolix is a novel, orally available nonpeptide GnRH antagonist. OBJECTIVE: Our objective was to evaluate the safety, pharmacokinetics, and inhibitory effects on gonadotropins and estradiol of single-dose and 7-d elagolix administration to healthy premenopausal women. DESIGN: This was a first-in-human, double-blind, placebo-controlled, single- and multiple-dose study with sequential dose escalation. PARTICIPANTS: Fifty-five healthy, regularly cycling premenopausal women participated. INTERVENTIONS: Subjects were administered a single oral dose of 25-400 mg or placebo. In a second arm of the study, subjects received placebo or 50, 100, or 200 mg once daily or 100 mg twice daily for 7 d. Treatment was initiated on d 7 (+/-1) after onset of menses. MAIN OUTCOME MEASURES: Safety, tolerability, pharmacokinetics, and serum LH, FSH, and estradiol concentrations were assessed. RESULTS:Elagolix was well tolerated and rapidly bioavailable after oral administration. Serum gonadotropins declined rapidly. Estradiol was suppressed by 24 h in subjects receiving at least 50 mg/d. Daily (50-200 mg) or twice-daily (100 mg) administration for 7 d maintained low estradiol levels (17 +/- 3 to 68 +/- 46 pg/ml) in most subjects during late follicular phase. Effects of the compound were rapidly reversed after discontinuation. CONCLUSIONS: Oral administration of a nonpeptide GnRH antagonist, elagolix, suppressed the reproductive endocrine axis in healthy premenopausal women. These results suggest that elagolix may enable dose-related pituitary and gonadal suppression in premenopausal women as part of treatment strategies for reproductive hormone-dependent disease states.
RCT Entities:
CONTEXT: Parenteral administration of peptide GnRH analogs is widely employed for treatment of endometriosis and fibroids and in assisted-reproductive therapy protocols. Elagolix is a novel, orally available nonpeptide GnRH antagonist. OBJECTIVE: Our objective was to evaluate the safety, pharmacokinetics, and inhibitory effects on gonadotropins and estradiol of single-dose and 7-d elagolix administration to healthy premenopausal women. DESIGN: This was a first-in-human, double-blind, placebo-controlled, single- and multiple-dose study with sequential dose escalation. PARTICIPANTS: Fifty-five healthy, regularly cycling premenopausal women participated. INTERVENTIONS: Subjects were administered a single oral dose of 25-400 mg or placebo. In a second arm of the study, subjects received placebo or 50, 100, or 200 mg once daily or 100 mg twice daily for 7 d. Treatment was initiated on d 7 (+/-1) after onset of menses. MAIN OUTCOME MEASURES: Safety, tolerability, pharmacokinetics, and serum LH, FSH, and estradiol concentrations were assessed. RESULTS:Elagolix was well tolerated and rapidly bioavailable after oral administration. Serum gonadotropins declined rapidly. Estradiol was suppressed by 24 h in subjects receiving at least 50 mg/d. Daily (50-200 mg) or twice-daily (100 mg) administration for 7 d maintained low estradiol levels (17 +/- 3 to 68 +/- 46 pg/ml) in most subjects during late follicular phase. Effects of the compound were rapidly reversed after discontinuation. CONCLUSIONS: Oral administration of a nonpeptide GnRH antagonist, elagolix, suppressed the reproductive endocrine axis in healthy premenopausal women. These results suggest that elagolix may enable dose-related pituitary and gonadal suppression in premenopausal women as part of treatment strategies for reproductive hormone-dependent disease states.
Authors: John Trachtenberg; Marc Gittleman; Christopher Steidle; Winston Barzell; William Friedel; Dennis Pessis; Nick Fotheringham; Marilyn Campion; Marc B Garnick Journal: J Urol Date: 2002-04 Impact factor: 7.450
Authors: Bruce Carr; W Paul Dmowski; Chris O'Brien; Ping Jiang; Joshua Burke; Roland Jimenez; Elizabeth Garner; Kristof Chwalisz Journal: Reprod Sci Date: 2014-09-23 Impact factor: 3.060
Authors: Bruce R Carr; Elizabeth A Stewart; David F Archer; Ayman Al-Hendy; Linda Bradley; Nelson B Watts; Michael P Diamond; Jingjing Gao; Charlotte D Owens; Kristof Chwalisz; W Rachel Duan; Ahmed M Soliman; Matthew B Dufek; James A Simon Journal: Obstet Gynecol Date: 2018-11 Impact factor: 7.661
Authors: Insa Winzenborg; Ahmed Nader; Akshanth R Polepally; Mohan Liu; Jacob Degner; Cheri E Klein; Nael M Mostafa; Peter Noertersheuser; Juki Ng Journal: Clin Pharmacokinet Date: 2018-10 Impact factor: 6.447
Authors: Ivan Urits; Leena Adamian; Paulo Miro; Jessica Callan; Parth M Patel; Megha Patel; Amnon A Berger; Hisham Kassem; Alan D Kaye; Omar Viswanath Journal: Psychopharmacol Bull Date: 2020-10-15